CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of prostate cancer.
  
  PURPOSE STATEMENT
  By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with prostate cancer.
  
  LEARNING OBJECTIVES

  • Appraise published research and current guidelines for the management of prostate cancer among patients with biochemical recurrence after local treatment, and counsel appropriate candidates regarding the potential benefits of systemic therapy.
  • Evaluate the published research database supporting the FDA approvals of secondary hormonal agents in the management of nonmetastatic castration-resistant prostate cancer (CRPC) and metastatic hormone-sensitive prostate cancer, and apply this information in the discussion of nonresearch treatment options with patients.
  • Recognize how prior therapeutic exposure and patient and disease characteristics factor into the selection and sequencing of systemic treatments for metastatic CRPC (mCRPC).
  • Assess available research with the use of PARP inhibitors alone or in combination with secondary hormonal therapies for mCRPC, and consider the current and potential role of these agents for patients with and without homologous recombination repair gene mutations.
  • Appreciate available and emerging clinical research documenting the efficacy of PSMA-targeted radioligand therapy for patients with PSMA-positive mCRPC, and consider the current and future clinical role of this strategy.

  ACCREDITATION STATEMENT
  Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
  
  CREDIT DESIGNATION STATEMENT
  This educational activity for 1.75 contact hours is provided by RTP during the period of June 2023 to June 2024.
  
  This activity is awarded 1.75 ANCC pharmacotherapeutic contact hours.
  
  ONCC/ILNA CERTIFICATION INFORMATION
  The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/ONS2023/Prostate/ILNA.
  
  ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.
  
  FOR SUCCESSFUL COMPLETION
  To receive credit, participants should read the learning objectives and faculty disclosures, watch the video, complete the post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ONS2023/Prostate/NCPD.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Neeraj Agarwal, MD, FASCO
  Professor of Medicine
  Senior Director for Clinical Research Innovation
  Huntsman Cancer Institute Presidential Endowed Chair of Cancer Research
  Director, Center of Investigational Therapeutics
  Director, Genitourinary Oncology Program
  Huntsman Cancer Institute, University of Utah (NCI-CCC)
  Salt Lake City, Utah
  
  Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Calithera Biosciences, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Immunomedics Inc, Janssen Biotech Inc, Lilly, MEI Pharma Inc, Merck; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bavarian Nordic, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Calithera Biosciences, Celldex Therapeutics, Clovis Oncology, Eisai Inc, EMD Serono Inc, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Immunomedics Inc, Janssen Biotech Inc, Lilly, Lumos Pharma, Medivation Inc, a Pfizer Company, Merck, Nektar, Novartis, Pfizer Inc, Prometheus Laboratories Inc, Rexahn Pharmaceuticals Inc, Roche Laboratories Inc, Sanofi, Seagen Inc, Takeda Pharmaceuticals USA Inc, TRACON Pharmaceuticals Inc.
  
  Kathy D Burns, RN, MSN, AGACNP-BC, OCN
  Genitourinary Medical Oncology
  City of Hope Comprehensive Cancer Center
  Duarte, California
  
  No relevant conflicts of interest to disclose.
  
  Susan K Roethke, MSN, CRNP, AOCNP, ANP-BC
  Genitourinary Medical Oncology
  Fox Chase Cancer Center
  Philadelphia, Pennsylvania
  
  No relevant conflicts of interest to disclose.
  
  Sandy Srinivas, MD
  Professor of Oncology
  Clinical Research Leader, GU Oncology
  Stanford University
  Stanford, California
  
  Advisory Committee and Consulting Agreements: Janssen Biotech Inc, Merck, Novartis, Seagen Inc; Contracted Research: Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Celgene Corporation, Exelixis Inc, Regeneron Pharmaceuticals Inc, Seagen Inc; Data and Safety Monitoring Board/Committee: Pfizer Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Merck, Novartis, and Pfizer Inc.
  
  Release date: June 2022
  Expiration date: June 2023
  
  There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.